Betting on Safety: The IoM Report's Impact on Wall Street
This article was originally published in RPM Report
Executive Summary
The Institute of Medicine is recommending big changes in how FDA deals with drug safety issues. Is it possible that will be good news on Wall Street? Drug safety expert and managing director of investment company Symphony Capital, Alastair Wood, weighs in.